AZD0120
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Pressure score
54
Momentum score
51
Why This Matters
Roche is a direct competitive threat because it is already approved in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Approved
- Stage gap
- Competitor is materially ahead in development and could reach market before the signal asset.
- Market share risk
- Share risk is emerging — primarily strategic positioning rather than immediate revenue displacement.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Neurology · Autoimmune Disease · Trial Update · This positions ENSPRYNG as a potential first-line treatment for MOGAD, a disease with no current approved therapies, impacting the competitive landscape significantly.
Source: Roche
View source documentRelated Signal
AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #3 of 3
Bristol Myers Squibb
1 competitive finding
Top program: AZD0120
- Pressure
- 62
- Momentum
- 20
- Threat
- direct competitor
- Stage
- Phase III
62Bristol Myers SquibbMediumAZD0120·Phase III
Pfizer
1 competitive finding
Top program: AZD0120
- Pressure
- 60
- Momentum
- 14
- Threat
- emerging competitor
- Stage
- Phase I
60PfizerMediumAZD0120·Phase I
Roche
2 competitive findings
Top program: AZD0120
- Pressure
- 54
- Momentum
- 51
- Threat
- direct competitor
- Stage
- Approved
54RocheMediumAZD0120·Approved